One center's experience with OKT3 in renal transplantation: patient and graft survival, complications, and cost analysis.
Güz
G
G
Department of Nephrology, Başkent University Faculty of Medicine, Ankara, Turkey.
Emiroğlu
R
R
Demirhan
B
B
Köseoğlu
F
F
Karakayali
H
H
Bilgin
N
N
D000328:Adult; D003404:Creatinine / Q000097:blood; D016527:Drug Costs; D004351:Drug Resistance; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011183:Postoperative Complications; D019233:Retreatment; D013256:Steroids / Q000627:therapeutic use; D016019:Survival Analysis
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D003404:Creatinine